Skip to main content
PriceTargets.com logo

NASDAQ:SLNO - Soleno Therapeutics Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $8.67
  • Forecasted Upside: 758.09 %
  • Number of Analysts: 3
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 3 Buy Ratings
  • 0 Strong Buy Ratings
$1.01 As of 05/17/2021 01:00 AM ET
▲ +0.04 (4.12%)
1 month | 3 months | 12 months
Get New Soleno Therapeutics Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for SLNO and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for SLNO

i We calculate consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). Our consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. Our consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
$8.67
▲ +758.09% Upside Potential
This price target is based on 3 analysts offering 12 month price targets for Soleno Therapeutics in the last 3 months. The average price target is $8.67, with a high forecast of $10.00 and a low forecast of $8.00. The average price target represents a 758.09% upside from the last price of $1.01.

Buy

The current consensus among 3 investment analysts is to buy stock in Soleno Therapeutics. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
11/24/2019
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
2/22/2020
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
5/22/2020
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
8/20/2020
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
11/18/2020
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
2/16/2021
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
4/17/2021
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
5/17/2021

Latest Recommendations

  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
3/3/2021OppenheimerReiterated RatingBuy$8.00High
i
9/29/2020GuggenheimInitiated CoverageBuy$8.00High
i
6/5/2020LaidlawReiterated RatingBuy$10.00Low
i
Rating by Yale Jen at Laidlaw
1/10/2020Craig HallumInitiated CoverageBuy$8.00High
i
12/23/2019LaidlawInitiated CoverageBuyHigh
i
Rating by Francois Brisebois at Laidlaw
12/23/2019OppenheimerInitiated CoverageOutperform$10.00High
i
7/8/2019LaidlawInitiated CoverageBuy$10.00High
i
12/20/2018Maxim GroupSet Price TargetBuy$5.00Low
i
Rating by Jason Kolbert at Maxim Group
11/16/2018Maxim GroupSet Price TargetBuy$4.00High
i
Rating by Caroline Palomeque at Maxim Group
10/8/2018Maxim GroupSet Price TargetBuy$4.00High
i
Rating by Caroline Palomeque at Maxim Group
9/17/2018Maxim GroupReiterated RatingBuy$4.00Low
i
Rating by Caroline Palomeque at Maxim Group
8/15/2018Maxim GroupSet Price TargetBuy$4.00High
i
Rating by Caroline Palomeque at Maxim Group
7/30/2018Maxim GroupSet Price TargetBuy$4.00High
i
Rating by Caroline Palomeque at Maxim Group
6/22/2018Roth CapitalInitiated CoverageBuy$14.00High
i
Rating by Y. Rahimi at Roth Capital
5/16/2018Maxim GroupSet Price TargetBuy$4.00Medium
i
Rating by Caroline Palomeque at Maxim Group
5/16/2018Noble FinancialSet Price TargetBuy$4.00Low
i
Rating by Caroline Palomeque at Noble Financial
4/2/2018Maxim GroupSet Price TargetBuy$4.00High
i
Rating by Jason McCarthy at Maxim Group
2/13/2018Maxim GroupSet Price TargetBuy ➝ Buy$8.00 ➝ $4.00Low
i
Rating by Jason Kolbert at Maxim Group
12/8/2017Maxim GroupSet Price TargetBuy$8.00Low
i
Rating by Jason Kolbert at Maxim Group
10/12/2017Maxim GroupSet Price TargetBuy$25.00N/A
i
Rating by Jason Kolbert at Maxim Group
9/13/2017Maxim GroupReiterated RatingBuy$25.00Medium
i
Rating by Jason Kolbert at Maxim Group
8/14/2017Maxim GroupSet Price TargetBuy$25.00High
i
Rating by Jason Kolbert at Maxim Group
7/5/2017Maxim GroupSet Price TargetBuy$25.00Medium
i
Rating by Jason Kolbert at Maxim Group
5/4/2017Maxim GroupSet Price TargetBuy$25.00High
i
Rating by Jason McCarthy at Maxim Group
3/11/2017Maxim GroupSet Price TargetBuy$25.00Low
i
Rating by Jason McCarthy at Maxim Group
1/26/2017Maxim GroupUpgradeHold ➝ Buy$25.00N/A
i
Rating by Jason Kolbert at Maxim Group
11/23/2016Maxim GroupDowngradeBuy ➝ HoldN/A
i
Rating by Jason Kolbert at Maxim Group
6/15/2016Maxim GroupReiterated RatingBuyN/A
i
Rating by Benji Star at Maxim Group
6/8/2016Maxim GroupReiterated RatingBuy$15.00N/A
i
Rating by Sharon Stein at Maxim Group
(Data available from 5/18/2016 forward)
Soleno Therapeutics logo
Soleno Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutics for the treatment of rare diseases. Its lead candidate is Diazoxide Choline Controlled-Release (DCCR), a once-daily oral tablet for the treatment of Prader-Willi Syndrome (PWS), is being evaluated in a Phase III clinical development program. The company was formerly known as Capnia, Inc. and changed its name to Soleno Therapeutics, Inc. in May 2017. Soleno Therapeutics has collaboration with Vanderbilt University to discover and develop next generation K(ATP) channel activators for the treatment of rare diseases. Soleno Therapeutics, Inc. was incorporated in 1999 and is headquartered in Redwood City, California.
Read More

Today's Range

Now: $1.01
$0.95
$1.05

50 Day Range

MA: $1.17
$0.97
$1.31

52 Week Range

Now: $1.01
$0.93
$4.39

Volume

519,174 shs

Average Volume

1,537,699 shs

Market Capitalization

$80.52 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.71

Frequently Asked Questions

What sell-side analysts currently cover shares of Soleno Therapeutics?

The following Wall Street sell-side analysts have issued stock ratings on Soleno Therapeutics in the last twelve months: Guggenheim, Laidlaw, Oppenheimer Holdings Inc., and Zacks Investment Research.
View the latest analyst ratings for SLNO.

What is the current price target for Soleno Therapeutics?

3 Wall Street analysts have set twelve-month price targets for Soleno Therapeutics in the last year. Their average twelve-month price target is $8.67, suggesting a possible upside of 758.1%. Laidlaw has the highest price target set, predicting SLNO will reach $10.00 in the next twelve months. Oppenheimer Holdings Inc. has the lowest price target set, forecasting a price of $8.00 for Soleno Therapeutics in the next year.
View the latest price targets for SLNO.

What is the current consensus analyst rating for Soleno Therapeutics?

Soleno Therapeutics currently has 3 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe SLNO will outperform the market and that investors should add to their positions of Soleno Therapeutics.
View the latest ratings for SLNO.

What other companies compete with Soleno Therapeutics?

Other companies that are similar to Soleno Therapeutics include Edap Tms, Second Sight Medical Products, FONAR, IRIDEX, BioSig Technologies, Electromed, ENDRA Life Sciences, electroCore, Fc Global Realty, Helius Medical Technologies, ReShape Lifesciences, Viveve Medical, Nuwellis, Precision Optics and Star Equity.

How do I contact Soleno Therapeutics' investor relations team?

Soleno Therapeutics' physical mailing address is 203 REDWOOD SHORES PARKWAY SUITE 500, REDWOOD CITY CA, 94065. The company's listed phone number is 650-213-8444 and its investor relations email address is [email protected] The official website for Soleno Therapeutics is www.soleno.life.